title: Late cardiotoxicity after treatment for Hodgkin lymphoma.
abstract: We assessed cardiovascular disease (CVD) incidence in 1474 survivors of Hodgkin lymphoma (HL) younger than 41 years at treatment (1965-1995). Multivariable Cox regression and competing risk analyses were used to quantify treatment effects on CVD risk. After a median follow-up of 18.7 years, risks of myocardial infarction (MI) and congestive heart failure (CHF) were strongly increased compared with the general population (standardized incidence ratios [SIRs] = 3.6 and 4.9, respectively), resulting in 35.7 excess cases of MI and 25.6 excess cases of CHF per 10 000 patients/year. SIRs of all CVDs combined remained increased for at least 25 years and were more strongly elevated in younger patients. Mediastinal radiotherapy significantly increased the risks of MI, angina pectoris, CHF, and valvular disorders (2- to 7-fold). Anthracyclines significantly added to the elevated risks of CHF and valvular disorders from mediastinal RT (hazard ratios [HRs] were 2.81 and 2.10, respectively). The 25-year cumulative incidence of CHF after mediastinal radiotherapy and anthracyclines in competing risk analyses was 7.9%. In conclusion, risks of several CVDs are 3- to 5-fold increased in survivors of HL compared with the general population, even after prolonged follow-up, leading to increasing absolute excess risks over time. Anthracyclines further increase the elevated risks of CHF and valvular disorders from mediastinal radiotherapy.
authors.affiliation: Department of Radiotherapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
authors.forename: Berthe M P
authors.initials: BM
authors.lastname: Aleman
authors.forename: Alexandra W
authors.initials: AW
authors.lastname: van den Belt-Dusebout
authors.forename: Marie L
authors.initials: ML
authors.lastname: De Bruin
authors.forename: Mars B
authors.initials: MB
authors.lastname: van 't Veer
authors.forename: Margreet H A
authors.initials: MH
authors.lastname: Baaijens
authors.forename: Jan Paul
authors.initials: JP
authors.lastname: de Boer
authors.forename: Augustinus A M
authors.initials: AA
authors.lastname: Hart
authors.forename: Willem J
authors.initials: WJ
authors.lastname: Klokman
authors.forename: Marianne A
authors.initials: MA
authors.lastname: Kuenen
authors.forename: Gabey M
authors.initials: GM
authors.lastname: Ouwens
authors.forename: Harry
authors.initials: H
authors.lastname: Bartelink
authors.forename: Flora E
authors.initials: FE
authors.lastname: van Leeuwen
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology*; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D015996:Survival Rate; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents